Microglia

Microglia

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Microglia</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000129](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000129)</td>
</tr>
<tr>
<td class="label">Protein/Receptor</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>TREM2</td>
</tr>
<tr>
<td class="label">CX3CR1</td>
<td>CX3CR1</td>
</tr>
<tr>
<td class="label">P2RY12</td>
<td>P2RY12</td>
</tr>
<tr>
<td class="label">TMEM119</td>
<td>TMEM119</td>
</tr>
<tr>
<td class="label">IBA1</td>
<td>AIF1</td>
</tr>
<tr>
<td class="label">CD33</td>
<td>CD33</td>
</tr>
<tr>
<td class="label">NLRP3</td>
<td>NLRP3</td>
</tr>
<tr>
<td class="label">C1Q</td>
<td>C1QA/B/C</td>
</tr>
<tr>
<td class="label">CSF1R</td>
<td>CSF1R</td>
</tr>
<tr>
<td class="label">Resource</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Allen Human Brain Atlas</td>
<td>Transcriptomic data across adult brain regions</td>
</tr>
<tr>
<td class="label">BrainSpan</td>
<td>Developmental brain transcriptome</td>
</tr>
<tr>
<td class="label">Allen Cell Type Atlas</td>
<td>Single-cell expression data</td>
</tr>
<tr>
<td class="label">Allen Mouse Brain Atlas</td>
<td>Mouse brain connectivity and expressi

Microglia

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Microglia</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000129](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000129)</td>
</tr>
<tr>
<td class="label">Protein/Receptor</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>TREM2</td>
</tr>
<tr>
<td class="label">CX3CR1</td>
<td>CX3CR1</td>
</tr>
<tr>
<td class="label">P2RY12</td>
<td>P2RY12</td>
</tr>
<tr>
<td class="label">TMEM119</td>
<td>TMEM119</td>
</tr>
<tr>
<td class="label">IBA1</td>
<td>AIF1</td>
</tr>
<tr>
<td class="label">CD33</td>
<td>CD33</td>
</tr>
<tr>
<td class="label">NLRP3</td>
<td>NLRP3</td>
</tr>
<tr>
<td class="label">C1Q</td>
<td>C1QA/B/C</td>
</tr>
<tr>
<td class="label">CSF1R</td>
<td>CSF1R</td>
</tr>
<tr>
<td class="label">Resource</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Allen Human Brain Atlas</td>
<td>Transcriptomic data across adult brain regions</td>
</tr>
<tr>
<td class="label">BrainSpan</td>
<td>Developmental brain transcriptome</td>
</tr>
<tr>
<td class="label">Allen Cell Type Atlas</td>
<td>Single-cell expression data</td>
</tr>
<tr>
<td class="label">Allen Mouse Brain Atlas</td>
<td>Mouse brain connectivity and expression</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Role</td>
</tr>
<tr>
<td class="label">NF-κB</td>
<td>Pro-inflammatory gene transcription</td>
</tr>
<tr>
<td class="label">MAPK (p38, JNK)</td>
<td>Stress response, cytokine production</td>
</tr>
<tr>
<td class="label">STAT3</td>
<td>Anti-inflammatory response</td>
</tr>
<tr>
<td class="label">Gene/Protein</td>
<td>Function</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>Triggering receptor on myeloid cells 2; triggers microglial activation</td>
</tr>
<tr>
<td class="label">CX3CR1</td>
<td>Fractalkine receptor; regulates microglial surveillance</td>
</tr>
<tr>
<td class="label">CD33</td>
<td>Sialic acid-binding immunoglobulin-like lectin; modulates phagocytosis</td>
</tr>
<tr>
<td class="label">CR1</td>
<td>Complement receptor 1; mediates complement activation</td>
</tr>
<tr>
<td class="label">PLD3</td>
<td>Phospholipase D3; regulates lysosomal function</td>
</tr>
<tr>
<td class="label">ABCA7</td>
<td>ATP-binding cassette transporter A7; lipid transport</td>
</tr>
<tr>
<td class="label">SORL1</td>
<td>Sortilin-related receptor; vesicle trafficking</td>
</tr>
<tr>
<td class="label">IL1A</td>
<td>Interleukin-1 alpha; pro-inflammatory cytokine</td>
</tr>
<tr>
<td class="label">IL1B</td>
<td>Interleukin-1 beta; major inflammatory mediator</td>
</tr>
<tr>
<td class="label">TNF</td>
<td>Tumor necrosis factor alpha; inflammatory signaling</td>
</tr>
<tr>
<td class="label">CCL2</td>
<td>CC chemokine ligand 2; monocyte recruitment</td>
</tr>
<tr>
<td class="label">CXCL10</td>
<td>Chemokine CXCL10; inflammatory chemokine</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Role in Microglia</td>
</tr>
<tr>
<td class="label">TREM2-DAP12 signaling</td>
<td>Phagocytosis, survival</td>
</tr>
<tr>
<td class="label">NF-κB signaling</td>
<td>Inflammation</td>
</tr>
<tr>
<td class="label">cGAS-STING pathway</td>
<td>Type I interferon response</td>
</tr>
<tr>
<td class="label">PPAR-γ signaling</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Variant</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>R47H, R62H</td>
</tr>
<tr>
<td class="label">CD33</td>
<td>rs3865444</td>
</tr>
<tr>
<td class="label">PLCG2</td>
<td>M28L</td>
</tr>
<tr>
<td class="label">ABI3</td>
<td>W262</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>G2019S</td>
</tr>
<tr>
<td class="label">GBA1</td>
<td>N370S</td>
</tr>
</table>

Microglia are the resident immune cells of the central nervous system (CNS), acting as the brain's primary defense, surveillance, and cleanup cells. They play critical roles in development, injury, disease, and have emerged as central players in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders.

Overview

Microglia are unique innate immune cells that: [@hanisch2007]

• Originate from yolk sac progenitors during embryonic development, distinct from bone marrow-derived macrophages[1]
• 自我更新 (self-renew) in the adult brain through local proliferation
• Survey the CNS environment continuously via dynamic process motility (~2.5 μm/hour)
• Respond rapidly to injury and infection with stereotypical morphological and molecular changes
• Prune synapses during development and adulthood, sculpting neural circuits
• Exist in multiple activation states ranging from surveying to disease-associated phenotypes

Morphology

Microglia are the resident immune cells of the central nervous system: [@kettenmann2011]

• Cell Body: Small, elongated or spherical soma (5-10 μm)
• Processes: Highly ramified, dynamic processes that constantly survey the CNS parenchyma
• Morphological States:
• Ramified (surveying): Resting state with extensive branching
• Amoeboid: Activated, migratory state
• Gitter cells: Engulfed debris-containing cells
• Special Features: Express CX3CR1 receptor, CD45, Iba1, TMEM119

Patch-seq Profile

Microglial electrophysiological properties (distinct from neurons): [@ransohoff2009]

• Resting Membrane Potential: -20 to -10 mV (less negative than neurons)
• Ion Channels: Predominantly potassium channels (K+), some sodium channels upon activation
• Response to ATP: P2X/P2Y receptor-mediated calcium signaling and process extension
• Phagocytic Activity: Capacity for engulfment of synapses, debris, and pathogens

Layer & Region Distribution

• Distribution: Throughout the CNS, including all brain regions and spinal cord
• Density Variations: Higher density in hippocampus, cortex, and basal ganglia
• Regional Specialization:
• White matter: Lower density
• Gray matter: Higher density
• Perivascular spaces: Specialized macrophage populations

Multi-Taxonomy Classification

Taxonomy Database Cross-References

Morphology & Electrophysiology

• Morphology: microglial cell (source: Cell Ontology)
• Morphology can be inferred from Cell Ontology classification

Classification & Lineage

• Parent Classification: Immune
• Full Lineage: Glial > Immune > Microglia
• Brain Regions: Widespread (all brain regions), Higher density in gray matter

PanglaoDB Marker Cross-References

• Unknown (PanglaoDB):

External Database Links

• [Cell Ontology (CL:0000129)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000129)
• [OBO Foundry (CL:0000129)](http://purl.obolibrary.org/obo/CL_0000129)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [Human Cell Atlas](https://www.humancellatlas.org/)
• [PanglaoDB](https://panglaodb.se/)

Origin and Development

Microglia arise from primitive macrophages in the embryonic yolk sac: [@lawson1990]

The transcription factor PU.1 and CSF1R are essential for microglial development. The adult microglia transcriptome comprises ~1,000 differentially expressed genes, with Tmem119, P2ry12, and Cx3cr1 as canonical markers[2]. [@davalos2005]

Surveillance and Homeostatic Functions

Continuous Surveying

Resting microglia (now termed "surveying microglia") extend and retract processes: [@nimmerjahn2005]

• Process motility: 1-2 μm per minute
• Territorial coverage: Non-overlapping domains
• Response to ATP: P2Y12 receptor-mediated chemotaxis toward injury
• Calcium signaling: Spontaneous calcium waves in process tips

Synaptic Pruning

Microglia eliminate inappropriate synapses during development and adulthood: [@wake2009]

• Complement-mediated pruning: C1q tagging, C3-CR3 pathway
• Phagocytic removal: MEGF10 and MERTK receptors
• Activity-dependent: More active synapses are preserved
• Developmental windows: Peak pruning in early postnatal period

Trophic Support

Microglia secrete growth factors supporting neuron survival: [@hammond2019]

• BDNF (Brain-Derived Neurotrophic Factor)
• GDNF (Glial Cell Line-Derived Neurotrophic Factor)
• IGF-1 (Insulin-Like Growth Factor 1)

Disease-Associated Microglia (DAM)

In neurodegenerative conditions, microglia transition to a disease-associated phenotype: [@ginhoux2010]

DAM Stage 1 (Early)

• Triggered by: Amyloid-β, α-synuclein, TREM2 ligands
• Features: Downregulation of P2ry12, Tmem119; upregulation of Apoe
• Metabolic shift: Glycolysis enhancement

DAM Stage 2 (Late)

• Triggered by: Continued pathology, TREM2 activation
• Features: Upregulation of inflammation genes, lysosomal genes
• Phagocytic capacity: Increased but may be dysfunctional
• Iron accumulation: Ferritin upregulation

Role in Alzheimer's Disease

Amyloid Clearance

Microglia attempt to clear amyloid-β through: [@paolicelli2011]

• Receptor-mediated phagocytosis: TREM2, CD36, SR-A
• Secreted proteases: MMPs, IDE
• NLRP3 inflammasome activation: IL-1β production

• Inflammasome hyperactivation: Excessive IL-1β, IL-18
• Phagocytic dysfunction: Impaired clearance despite increased uptake
• Pro-inflammatory phenotype: TNF-α, NOS2 upregulation

Tau Pathology

Microglia contribute to tau spread through: [@sims2017]

• Inflammation-driven tau phosphorylation: GSK3β, CDK5 activation
• Tau uptake and release: Propagating pathology between neurons
• NLRP3 inflammasome: Accelerates tau aggregation

Genetic Evidence

AD risk genes highlight microglial involvement: [@hirsch2009]

• TREM2: Loss-of-function increases risk ~3-4x
• CD33: Sialic acid receptor affecting phagocytosis
• PLCG2: Phospholipase C gamma 2, immune signaling
• ABI3: Involved in TREM2 signaling[5]

Role in Parkinson's Disease

Substantia Nigra Vulnerability

Microglia in the substantia nigra are particularly responsive: [@heneka2015]

• High baseline inflammation: More primed than other regions
• Dopaminergic neuron susceptibility: Mitochondrial stress signals
• α-Synuclein clearance: Attempted but often ineffective

α-Synuclein Clearance

Microglia attempt to clear α-synuclein aggregates:

• TLR2/TLR4 recognition: Pattern recognition receptors
• Upregulation in PD: Increased TLR expression
• Impaired clearance: Accumulation leads to chronic activation
• Spread hypothesis: Microglia may propagate pathology

Neuroinflammation

Chronic microglial activation in PD:

• Pro-inflammatory cytokines: TNF-α, IL-1β, IL-6
• Oxidative stress: iNOS, NADPH oxidase
• Excitotoxicity: Glutamate transporter dysfunction
• Progressive cycle: Neuronal damage → more inflammation[6]

Other Neurodegenerative Conditions

Amyotrophic Lateral Sclerosis (ALS)

• Astrocyte-microglia crosstalk: Mutant SOD1 triggers
• Motor neuron vulnerability: Pro-inflammatory microenvironment
• TREM2 variants: Modify disease progression

Multiple Sclerosis (MS)

• Demyelination: Active lesion microglia phagocytose myelin
• Remyelination failure: Pro-inflammatory environment blocks OPC differentiation
• EAE model: Microglia-driven disease

Frontotemporal Dementia (FTD)

• TREM2 variants: Increase risk similar to AD
• Progranulin deficiency: Microglial lysosomal dysfunction
• Inflammation: Early and persistent

Therapeutic Targeting

Anti-Inflammatory Approaches

• Minocycline: Microglial activation inhibitor (clinical trials in ALS, AD)
• NSAIDs: COX inhibitors (mixed results in AD prevention)
• JAK-STAT inhibitors: Blocking inflammatory signaling

Microglial Modulation

• TREM2 agonism: Enhancing DAM pathway
• CSF1R antagonists: Reducing microglial proliferation (e.g., pexidartinib)
• CB2 receptor agonists: Anti-inflammatory without psychoactive effects

Restoration of Homeostasis

• Phagocytosis enhancement: Clearing pathology
• Metabolic normalization: Mitochondrial function
• Iron chelation: Addressing ferroptosis in microglia

Emerging Strategies

• Microglia transplantation: iPSC-derived microglia
• Gene therapy: Modifying microglial function
• Nanoparticle delivery: Targeted anti-inflammatory drugs[7]

Key Proteins and Receptors

Research Methods

• In vivo imaging: Two-photon microscopy of microglia
• Single-cell RNA-seq: Profiling activation states
• Spatial transcriptomics: Region-specific microglial phenotypes
• iPSC-derived microglia: Disease modeling
• PET imaging: TSPO tracers for microglial activation

Role in Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP)

Corticobasal Syndrome

Microglial activation in CBS exhibits distinct patterns: [@cargillschantman2021]

• Asymmetric cortical involvement: More pronounced microglial activation in the affected hemisphere
• Tau pathology correlation: 4R-tau isoforms trigger microglial responses
• Motor cortex involvement: Primary sensorimotor cortex shows dense microglial clustering
• White matter microglia: Activated microglia in degenerating white matter tracts

• TREM2 variants: Modify disease progression in CBS
• CBA (corticobasal degeneration): Tau filaments initiate microglial proliferation
• NLRP3 inflammasome: Elevated in CBS cortex, drives IL-1β production
• Complement activation: C1q and C3b deposition on degenerating synapses

• TREM2 agonists may enhance pathological clearance
• Anti-inflammatory approaches must balance immune clearance
• CSF1R modulation could reduce proliferating microglia

Progressive Supranuclear Palsy

PSP shows prominent microglial involvement: [@holmberg2023]

• Brainstem predilection: Substantia nigra, globus pallidus, subthalamic nucleus
• Tau-loaded neurons: Surrounded by activated microglia
• Glial tau pathology: Tau in astrocytes and oligodendrocytes triggers microglial response

• Substantia nigra pars reticulata: High microglial density
• Globus pallidus interna: Tau pathology with microglial activation
• Superior colliculus: Midbrain involvement
• Frontal cortex: Progressive cortical involvement

• 4R-tau: Dominant isoform, unique microglial interactions
• MAPT H1 haplotype: Genetic risk factor affecting microglial responses
• Neuroinflammation: Chronic microglial activation drives progression
• Iron accumulation: Ferritin-laden microglia in PSP brains

• TSP0 PET: Elevated binding in PSP brainstem and basal ganglia
• CSF sTREM2: Biomarker of microglial activation
• Microglial priming: Age-related susceptibility

• TREM2 modulation: Enhancing clearance of tau
• Iron chelation: Reducing microglial iron burden
• Anti-inflammatory strategies: JAK-STAT inhibitors
• GFAP-targeting: Modulating astrocyte-microglia crosstalk

Common Mechanisms in CBS and PSP

Both CBS and PSP share microglial mechanisms:

• TREM2-dependent pathways: Genetic variants affect disease course
• NLRP3 inflammasome: Central inflammatory driver
• Complement-mediated synapse loss: Contributes to cognitive decline
• Iron dysregulation: Microglial iron accumulation
• Astrocyte-microglia crosstalk: Shared reactive phenotypes

Research and Clinical Implications

Microglial biomarkers for CBS/PSP: [@giacomucci2022]

• Imaging: TSP0 PET for in vivo activation
• CSF markers: sTREM2, YKL-40, IL-1β
• Genetic testing: TREM2, PLGCG2 variants
• Therapeutic trials: TREM2 agonists, anti-inflammatory agents

Summary

Microglia are dynamic CNS sentinels essential for brain health and central to neurodegenerative disease pathogenesis. Their dual roles in protection and pathology make them attractive therapeutic targets. Understanding the balance between beneficial surveillance and harmful inflammation, particularly in the DAM pathway, offers opportunities for modulating microglial function in AD, PD, and related disorders.

Cross-species Conservation

Cell Ontology IDs: CL:0000129

Conservation Overview: Evolutionarily ancient immune cells. Present in all vertebrates. Human microglia show unique transcriptional signatures compared to mouse (TREM2, CX3CR1 variants).

Ortholog Mapping: TREM2, CX3CR1, P2RY12 highly conserved. Human-specific microglial genes include MERTK, PROS1.

Sources: [Cell Ontology](https://purl.obolibrary.org/obo/cl.obo), PanglaoDB[1], Allen Cell Type Database

[1]: [PanglaoDB: Cell type markers](https://panglaodb.se/markers.html)

See Also

• [Microglia](/cell-types/microglia)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Multiple Sclerosis](/diseases/multiple-sclerosis)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Brain Atlas Resources

Data for Microglia from the Allen Brain Atlas:

• [Allen Cell Type Atlas - Microglia](https://celltypes.brain-map.org/) - Cell type characterization and expression
• [Allen Mouse Brain Atlas](https://mouse.brain-map.org/) - Mouse brain reference data

Expression Data Resources

Molecular Mechanisms

Microglia are the resident immune cells of the central nervous system, playing critical roles in brain development, homeostasis, and neurodegeneration.

Pattern Recognition & Innate Immunity

• TREM2 Signaling: Triggering receptor expressed on myeloid cells 2 (TREM2) recognizes amyloid plaques, triggers phagocytosis
• TLR Activation: Toll-like receptors (TLR2, TLR4) detect DAMPs, pathogen-associated molecular patterns
• Complement System: C1q, C3标记突触，参与突触修剪

Inflammatory Signaling Pathways

Cytokine & Chemokine Networks

• Pro-inflammatory cytokines: IL-1β, IL-6, TNF-α, IL-18 released by activated microglia
• Chemokines: CCL2, CXCL10 recruit peripheral immune cells
• Anti-inflammatory: IL-10, TGF-β limit excessive inflammation

Phagocytic Pathways

• TREM2-DAP12 signaling: Triggers phagocytosis of amyloid, cellular debris
• Complement-mediated phagocytosis: C3b opsonization, CR3 receptor recognition
• LC3-associated phagocytosis (LAP): Non-canonical autophagy for phagolysosome formation

Metabolic Reprogramming

• Aerobic glycolysis: Switch to Warburg-like metabolism for immune activation
• Oxidative burst: NADPH oxidase (NOX2) produces ROS for microbial killing
• Mitochondrial dynamics: Fusion/fission alterations in disease states

Disease-Specific Mechanisms

Alzheimer's Disease

• DAM (Disease-Associated Microglia): TREM2-dependent transcriptional response to amyloid
• TREM2 variants: Risk alleles (R47H, R62H) impair phagocytosis
• Amyloid clearance: Reduced ability to clear Aβ plaques

Parkinson's Disease

• α-Synuclein recognition: TLR2, TLR4 detect Lewy bodies
• Neuroinflammation: Chronic microglial activation, dopaminergic neuron loss
• LRRK2 mutations: G2019S enhances microglial inflammatory response

Mermaid Diagram: Microglia Activation States

Key Genes and Proteins

Microglia function is regulated by numerous genes and proteins:

Therapeutic Implications

Microglia represent key therapeutic targets in neurodegenerative diseases:

Disease-Modifying Approaches

• TREM2 agonists: Enhance microglial phagocytosis and amyloid clearance[@gomeznicola2015]
• CSF1R inhibitors: Deplete pro-inflammatory microglia (trial in AD)[@hanisch2007]
• CD33 inhibitors: Block inhibitory CD33 to enhance clearance[@kettenmann2011]

Neuroprotective Strategies

• CX3CR1 modulators: Enhance fractalkine signaling for neuroprotection
• Anti-inflammatory agents: Minimize chronic microglial activation
• NLRP3 inflammasome inhibitors: Target IL-1β production[@ransohoff2009]

Symptomatic Treatments

• Minocycline: Antibiotic with anti-inflammatory properties (trial in PD, AD)
• P2X7 antagonists: Target microglial P2X7 receptor for anti-inflammatory effects

Emerging Therapies

• Microglial replacement: iPSC-derived microglia transplantation
• Gene therapy: Deliver neurotrophic factors via microglia-targeted vectors
• Brain-penetrant immunomodulators: Next-generation anti-inflammatory drugs

Neurodegenerative Disease Connections

Alzheimer's Disease Mechanisms

Microglia interact with multiple AD-relevant pathways:

• Amyloid-beta clearance: TREM2-mediated phagocytosis
• Neuroinflammation: NF-κB, MAPK signaling cascades
• Complement activation: C1q, C3-mediated synapse elimination
• Tau pathology spread: Microglial transport of tau seeds

Parkinson's Disease Mechanisms

• Alpha-synuclein clearance: Impaired TLR-mediated recognition
• Neuroinflammation: Chronic TNF-α, IL-1β release
• Oxidative stress: NADPH oxidase activation
• Mitochondrial dysfunction: LRRK2 G2019S variant effects

Amyotrophic Lateral Sclerosis

• Non-cell autonomous toxicity: Astrocyte-microglia crosstalk
• Excitotoxicity: Glutamate transporter dysfunction
• Oxidative stress: SOD1 mutant effects

Multiple Sclerosis

• Demyelination: Active phagocytosis of myelin
• Blood-brain barrier: Peripheral immune cell recruitment

Frontotemporal Dementia

• TREM2 variants: Similar to AD risk profile
• Progranulin deficiency: Lysosomal dysfunction

Key Signaling Pathways

Key Therapeutic Targets

Currently in Development

• TREM2 monoclonal antibodies: Enhancing phagocytosis
• CSF1R inhibitors: Reducing microglial proliferation
• BTK inhibitors: Limiting inflammatory activation

Research Stage

• Microglial iPSC transplantation: Cell replacement therapy
• Gene editing: Correcting TREM2 variants
• Nanoparticle drug delivery: Targeted anti-inflammatory therapy

Genetic Risk Factors

Biomarkers

Microglial activation biomarkers:

• TSPO PET imaging: In vivo microglial activation
• CSF YKL-40: Chitinase-3-like protein 1
• CSF sTREM2: Soluble TREM2 fragment
• IL-1β, IL-6, TNF-α: Pro-inflammatory cytokines

Model Systems

• Primary cultured microglia: Rodent and human
• iPSC-derived microglia: Patient-specific models
• CX3CR1-GFP mice: In vivo imaging
• TREM2 knock-out mice: Genetic loss-of-function
• 5xFAD mice: Amyloid model with microglial changes
• α-Syn preformed fibrils: PD model

Future Directions

• Single-cell profiling of human microglia across disease states
• Spatial transcriptomics of microglia in situ
• Development of brain-penetrant microglial modulators
• Understanding microglial heterogeneity in different brain regions

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Phase-Separated Organelle Targeting](/hypothesis/h-ec731b7a) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: G3BP1
• [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
• [Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: C1QA
• [Metabolic Circuit Breaker via Lipid Droplet Modulation](/hypothesis/h-3d993b5d) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: PLIN2
• [Temporal Decoupling via Circadian Clock Reset](/hypothesis/h-019ad538) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: CLOCK
• [Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators](/hypothesis/h-ba3a948a) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: CX3CR1
• [Synthetic Biology Rewiring via Orthogonal Receptors](/hypothesis/h-e3506e5a) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: CNO
• [Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics](/hypothesis/h-513a633f) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: ANXA1

Related Analyses:

• [TREM2 agonism vs antagonism in DAM microglia](/analysis/SDA-2026-04-01-gap-001) &#x1f504;
• [Microglial subtypes in neurodegeneration — friend vs foe](/analysis/SDA-2026-04-02-gap-microglial-subtypes-20260402004119) &#x1f504;
• [TREM2 agonism vs antagonism in DAM microglia](/analysis/SDA-2026-04-02-gap-001) &#x1f504;
• [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Microglia discovered through SciDEX knowledge graph analysis:

<!-- scidex-demo:links:start -->

SciDEX Links

Related Hypotheses

• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — score 0.92; target SMPD1; neurodegeneration.
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — score 0.92; target CYP46A1; neurodegeneration.
• [SASP-Mediated Complement Cascade Amplification](/hypothesis/h-58e4635a) — score 0.91; target C1Q/C3; neurodegeneration.
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — score 0.85; target SST; Alzheimer's disease.

Related Analyses

• [TREM2 agonism vs antagonism in DAM microglia](/analyses/SDA-2026-04-01-gap-001)
• [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analyses/SDA-2026-04-01-gap-009)
• [Synaptic pruning by microglia in early AD](/analyses/SDA-2026-04-01-gap-v2-691b42f1)